Gilder Gagnon Howe & CO LLC Iveric Bio, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $5,143 - $7,767	-196 Reduced 0.27%	71,761 $2.82 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $6,254 - $8,227	-335 Reduced 0.46%	71,957 $1.75 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $568 - $790	-33 Reduced 0.05%	72,292 $1.55 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $233,524 - $461,831	-24,843 Reduced 25.57%	72,325 $1.3 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $776,795 - $1.61 Million	-85,175 Reduced 46.71%	97,168 $935,000
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $26,900 - $37,261	-2,214 Reduced 1.2%	182,343 $3.07 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $2.55 Million - $3.47 Million	184,557 New	184,557 $3.09 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.